Mylan to Make Amendments in its 2018 License Agreement with Revance for Biosimilar of BOTOX

 Mylan to Make Amendments in its 2018 License Agreement with Revance for Biosimilar of BOTOX

Biocon and Mylan’s Ogivri (trastuzumab, biosimilar) Receives Health Canada’s Approval for HER2-Positive Breast and Gastric Cancers

  • Mylan to pay $5M up front in addition to $25M (according to 2018 deal), contingent payments ~$100M, ~$225M milestones on the achievement of specified clinical and regulatory milestones and royalties on sales of the biosimilar in Mylan territories
  • The amendment is made in the extension of time for Mylan to develop and commercialize biosimilar of BOTOX (onabotulinumtoxinA). Additionally, Mylan must inform Revance by Aprl’20, or 30 days before the date of to deliver from the date that the Company provides Mylan with certain deliverables
  • BOTOX (onabotulinumtoxinA) is a neuromuscular agent, approved incontinence due to neurological conditions, prophylaxis of headache in patients with migraine, upper limb spasticity, cervical dystonia, and strabismus

Click here to read full press release/ article | Ref: Mylan | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post